Takeda, makers of Actos, Scraps Development of Type 2 Diabetes Drug

Daniels Tredennick Pharmaceutical and Mass Torts

Japanese pharmaceutical company Takeda is dropping plans to develop diabetes drug fasiglifam (TAK-875) because clinical trials showed participants developed dangerous side effects, including possible liver damage. This comes as a blow for the drugmaker as it scrambles to find another drug to take the place of its once best-selling Type 2 diabetes drug Actos. Takeda lost patent protection for Actos …